Resverlogix Corp.

RVX-T

Analysis and Opinions about RVX-T

Signal
Opinion
Expert
COMMENT
COMMENT
November 16, 2009
(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.
Show full opinionHide full opinion
Resverlogix Corp. (RVX-T)
November 16, 2009
(Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative.
COMMENT
COMMENT
August 6, 2009
Only process that can reverse a cholesterol situation. A lot of big pharmas are looking at the name. Looks pretty attractive at this level. This is at phase 2 and he prefers buying after phase 3.
Show full opinionHide full opinion
Only process that can reverse a cholesterol situation. A lot of big pharmas are looking at the name. Looks pretty attractive at this level. This is at phase 2 and he prefers buying after phase 3.
COMMENT
COMMENT
December 27, 2007
Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X).
Show full opinionHide full opinion
Resverlogix Corp. (RVX-T)
December 27, 2007
Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X).
DON'T BUY
DON'T BUY
March 26, 2007
Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe.
Show full opinionHide full opinion
Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe.
DON'T BUY
DON'T BUY
January 24, 2007
Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive.
Show full opinionHide full opinion
Resverlogix Corp. (RVX-T)
January 24, 2007
Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive.
Showing 1 to 5 of 5 entries
  • «
  • 1
  • »

Resverlogix Corp.(RVX-T) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for Resverlogix Corp. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Resverlogix Corp.(RVX-T) Frequently Asked Questions

What is Resverlogix Corp. stock symbol?

Resverlogix Corp. is a Canadian stock, trading under the symbol RVX-T on the Toronto Stock Exchange (RVX-CT). It is usually referred to as TSX:RVX or RVX-T

Is Resverlogix Corp. a buy or a sell?

In the last year, there was no coverage of Resverlogix Corp. published on Stockchase.

Is Resverlogix Corp. a good investment or a top pick?

Resverlogix Corp. was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Resverlogix Corp..

Why is Resverlogix Corp. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Resverlogix Corp. worth watching?

In the last year, there was no coverage of Resverlogix Corp. published on Stockchase.

What is Resverlogix Corp. stock price?

On 2020-06-05, Resverlogix Corp. (RVX-T) stock closed at a price of $0.59.